MSLN and ovarian carcinoma: Another study utilized the dual recognition of mesothelin (with an anti-mesothelin scFv-CD3ζ to provide signal 1) and folic receptor alpha (FRα) (with an anti-FRα scFv-CD28 to provide signal 2) to target ovarian cancer [33].